Brain function critically depends on a close matching between metabolic demands,
appropriate delivery of oxygen and nutrients, and removal of cellular waste. This matching …

Recent drug development efforts targeting Alzheimer's disease (AD) have failed to produce
effective disease-modifying agents for many reasons, including the substantial …

Increasing evidence recognizes Alzheimer's disease (AD) as a multifactorial and
heterogeneous disease with multiple contributors to its pathophysiology, including vascular …

Therapies targeting late events in Alzheimer's disease (AD), including aggregation of
amyloid beta (Aβ) and hyperphosphorylated tau, have largely failed, probably because they …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

INTRODUCTION In Alzheimer's disease (AD), the production of amyloid β (Aβ) oligomers
and downstream tau dysfunction are thought to cause neuronal damage, in particular a loss …

Cerebral blood flow (CBF) regulation is essential for normal brain function. The mammalian
brain has evolved a unique mechanism for CBF control known as neurovascular coupling …

Since the 2013 Nobel Prize was awarded for the discovery of vesicle trafficking, a subgroup
of nanovesicles called exosomes has been driving the research field to a new regime for …

Vascular contributions to cognitive impairment and dementia (VCID) are characterized by
the aging neurovascular unit being confronted with and failing to cope with biological insults …

Despite all scientific efforts and many protracted and expensive clinical trials, no new drug
has been approved by FDA for treatment of Alzheimer disease (AD) since 2003. Indeed …